The Helmholtz-Institute for Pharmaceutical Research Saarland (HIPS), a location of the Helmholtz Centre for Infection Research (HZI), teams up with the Global Antibiotic Research and Development Partnership (GARDP) to discover novel antibiotics. Ascenion, the HZI’s technology transfer partner, supported the deal.
The partners will focus on drug-resistant pathogens that are most threatening to public health according to WHO’s classification. HIPS will contribute its unique library of natural compounds to the global drug discovery initiative, which brings together leading institutes and public private partnerships to combat antibacterial resistance. Besides HIPS and GARDP, it embraces the open-access screening initiative CO-ADD and Calibr, the translational division of Scripps Research.
For further information see the HZI's press release
